Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206310
Status:
COMPLETED
Last Update Posted:
2010-11-19
First Post:
2005-09-16
Brief Title:
Crestor Versus Placebo in Subjects With Heart Failure
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized Double-Blind Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to investigate if rosuvastatin added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke time to first event
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D3562C00098 | None | None | None |
| CORONA | None | None | None |